Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 19.59 USD -1.21%
Market Cap: 1.4B USD
Have any thoughts about
Nurix Therapeutics Inc?
Write Note

Nurix Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nurix Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Nurix Therapeutics Inc
NASDAQ:NRIX
Cash from Operating Activities
-$81.4m
CAGR 3-Years
-906%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Nurix Therapeutics Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Nestled in the heart of the biotechnology wave, Nurix Therapeutics Inc. emerges as a pioneer in the burgeoning field of protein modulation. Founded with the ambition to transform drug discovery, the company focuses on manipulating the body’s complex system of protein degradation. Their mission orbits around harnessing the ubiquitin-proteasome system, a natural cellular process responsible for degrading unwanted proteins. Through this sophisticated dance of molecule manipulation, Nurix endeavors to tackle diseases that have eluded traditional drug discovery methods, aiming to control the fate of disease-causing proteins within the cellular ecosystem. Nurix’s business model thrives on a dual approach: proprietary drug development and strategic collaborations. The company pursues its own pipeline of novel therapeutics targeting oncology and immunology, seeking breakthroughs that could redefine treatments for cancer and immune-related diseases. Simultaneously, it partners with pharmaceutical giants, leveraging its DUB (Deubiquitinase) platform technology in exchange for upfront payments, research funding, and potential milestones. This hybrid strategy not only diversifies their revenue streams but also amplifies their scientific influence, positioning them as a vital contributor to the evolving landscape of biopharmaceutical innovation. Through these finely-tuned processes, Nurix crafts its path in the highly competitive biotech arena, striving to turn cutting-edge science into tangible healthcare solutions.

NRIX Intrinsic Value
9.25 USD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Nurix Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-81.4m USD

Based on the financial report for Nov 30, 2023, Nurix Therapeutics Inc's Cash from Operating Activities amounts to -81.4m USD.

What is Nurix Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-21%

Over the last year, the Cash from Operating Activities growth was 49%. The average annual Cash from Operating Activities growth rates for Nurix Therapeutics Inc have been -906% over the past three years , -21% over the past five years .

Back to Top